Huntington’s disease research news. In plain language. Written by scientists. For the global HD community.
Nearly a thousand HD family members converged on Baltimore, Maryland for the 2016 Huntington’s Disease Society of America’s Annual Convention. We normally don’t write reports from patient and family conferences, but there was something special about the atmosphere of this year’s Convention that compelled us to pen a brief update.
The National Institute for Health's Office for Research Integrity has ruled that Huntington's disease researcher Dr Paul Muchowski, formerly of the Gladstone Institutes at University of California San Francisco, committed "research misconduct by falsifying and fabricating data" in several applications for funding. What does this mean for Muchowski's published HD therapies research?
The immune system is thought to behave abnormally in Huntington's disease. Now, a drug that activates CB2 receptors on immune cells has been shown to improve symptoms and survival in HD mice - with interesting implications for the immune system as a target for HD therapies.
Are there connections between the body's immune system and the progression of Huntington's disease? New evidence suggests that correcting changes in the immune system could have real impact on brain aspects of HD.